 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| Y101D / YZY Biopharma
New P1/2 trial, Combination therapy, Metastases: A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 19, 2024
P1/2, N=71, Active, not recruiting, Sponsor: Wuhan YZY Biopharma Co., Ltd.
- || Y101D / YZY Biopharma
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Trial of Y101D, a PD-L1/TGF-? Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - Feb 14, 2024
P1, N=126, Active, not recruiting, Sponsor: Wuhan YZY Biopharma Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Mar 2024
- ||| Y101D / YZY Biopharma
New P1 trial, Metastases: A Trial of Y101D, a PD-L1/TGF-? Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - Aug 30, 2021
P1, N=126, Recruiting, Sponsor: Wuhan YZY Biopharma Co., Ltd.